NeuVax

NeuVax Logo

NeuVax is a cancer vaccine aimed at preventing the recurrence of breast cancer in patients who have completed standard treatment but are at risk of relapse. The vaccine is designed to stimulate the patient's immune system to target and destroy cancer cells that express a specific protein, HER2/neu. Despite the name, HER2/neu is expressed at low to intermediate levels in a subset of breast cancer patients, rather than the high levels associated with HER2-positive breast cancer. NeuVax is part of a broader category of cancer immunotherapy, which seeks to harness the body's immune system to fight cancer.

Development and Mechanism

NeuVax consists of the E75 peptide derived from the HER2/neu protein, combined with an immune system adjuvant, GM-CSF (Granulocyte-macrophage colony-stimulating factor), to enhance the immune response. The vaccine is administered as an injection under the skin (subcutaneously) and is intended to induce a cytotoxic T lymphocyte (CTL) response against cancer cells expressing HER2/neu.

The development of NeuVax is based on the premise that low to intermediate levels of HER2/neu expression, though not eligible for therapies like trastuzumab (Herceptin), could still be targeted by the immune system if properly stimulated. Clinical trials have been conducted to evaluate the efficacy and safety of NeuVax in preventing breast cancer recurrence, with mixed results influencing its progression through the regulatory approval process.

Clinical Trials

Clinical trials for NeuVax have included Phase I, II, and III studies, assessing its safety, optimal dosing, and efficacy in preventing the recurrence of breast cancer. The most notable of these, the PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expressions with NeuVax Treatment) trial, was a Phase III study. However, the development of NeuVax has faced challenges, including mixed results in terms of its efficacy in preventing cancer recurrence, which has impacted its progress toward regulatory approval.

Current Status

As of the last update, NeuVax has not received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the prevention of breast cancer recurrence. The future of NeuVax depends on the outcomes of ongoing and future clinical trials, which aim to better define its efficacy, safety profile, and potential role in breast cancer treatment.

Potential Impact

If proven effective, NeuVax could represent a significant advancement in the management of breast cancer, particularly for patients with low to intermediate HER2/neu expression who currently have limited targeted therapy options. By potentially reducing the risk of cancer recurrence, NeuVax could improve long-term outcomes and survival rates for a significant subset of breast cancer patients.

See Also

• Cancer vaccine
• Immunotherapy
• Breast cancer
• HER2/neu